Diastolic augmentation to assist in the treatment of in 1958 1 . Harken suggested that the rapid removal of blood from the femoral artery during systole and its replacement during diastole would assist cardiac output and unload the heart simultaneously 1,2 . Considering these principles an intra-aortic balloon pump (IABP) prototype was developed in 1962 and integrated into patient care in 1968 3, 4 . Initial clinical experience was mixed; while an improvement in haemodynamic function was demonstrated, mortality development has continued and practice has consequently changed dramatically. IABP has progressed to become an established treatment widely used in the setting of cardiac failure and potential cardiac compromise. There have been major improvements in patient outcome as well as dramatic reductions in morbidity and mortality rates 5 . Technological advance has allowed easier intraaortic balloon (IAB) catheter insertion, the provision of smaller catheters and a more . Time has also seen a change in IABP indications.
Traditional indications for IABP have included cardiogenic shock, myocardial ischaemia, failure to separate from cardiopulmonary bypass and severe acute mitral regurgitation . The increasing use of IABP, however, has seen its scope evolve to include additional applications such as the provision of haemodynamic support during or after cardiac catheterisation, preoperative insertion in high risk patients, the treatment of refractory unstable angina, refractory ventricular failure and ischaemia related to intractable ventricular arrhythmias 8 . Diversity of IABP use has also seen success in the augmentation vasospasm, in the anaesthetic management of high risk cardiac patients undergoing non-cardiac surgery, in the management of myocardial failure following severe postpartum haemorrhage and for circulatory support in septic shock [9] [10] [11] [12] [13] [14] [15] . hospitals with differences in IABP utilisation rates, indications and outcomes 16 . The purpose of this study was to review and describe current indications for IABP use and the impact these have on outcomes at an Australian cardiothoracic tertiary referral hospital. Recent establishment of large multinational registries containing data on IABP has afforded an opportunity for contrasting local practice . A secondary aim of this study was the comparison of aspects of application and outcomes at The Prince Charles Hospital (TPCH) with those of a large multinational IABP data registry. To meet these aims this study set out to answer the following research questions:
(including patient demographics and characteristics)?
for IABP at TPCH? Does IABP application and outcome significantly differ between TPCH and The Benchmark Counterpulsation Outcomes Registry?
Study patients and setting
funded public tertiary referral teaching hospital, with a predominantly cardiothoracic medical and surgical case-mix. It incorporates a 16-bed coronary care unit, (ICU) and an eight-bed general ICU. Admission to the coronary care unit or either ICU depends upon the 
What are the characteristics of TPCH IABP (including patient demographics and characteristics)?
Baseline clinical characteristics for the total TPCH population and IABP indications are shown in Table 1 . Participants were aged between 14 and 89 years. Of the 669 TPCH IABP cases, 599 were admitted to an ICU with a mean ICU length of stay percent of IABP patients cared for in ICU received mechanical ventilation for a mean of 59.3 hours ICU, 64 were managed in the coronary care unit only while 6 died in the operating room.
During the study period, 431 patients treated with IABP underwent cardiac surgery representing cardiac surgical operations were performed between (126 insertions) (Figure 1) .
IAB insertion was performed in the catheter cases were unrecorded). A percutaneous approach subject to a trans-aortic approach and three patients recorded).
What are the mortality and complication rates for IABP at TPCH?
relationship with in-hospital mortality despite a predominance of cardiothoracic patients (Figure 3 ). amputation was required in the TPCH series. All IABP outcomes are shown in Table 2 .
Does IABP application and outcome signifcantly differ between TPCH and The Benchmark Counterpulsation Outcome Registry?
The difference between TPCH and Benchmark IABP application and outcomes is shown in Tables  1 and 2 . TPCH was more likely to utilise IABP than Benchmark in the setting of: weaning from cardiopu;monary bypass; cardiogenic shock and ischaemia related to intractable ventricular arrhythmias. TPCH was less likely to utilise IABP than Benchmark in the setting of: catheter laboratory support; unstable refractory angina and mechanical complications due to acute myocardial infarction. TPCH demonstrated greater survival rates than Benchmark in the setting of weaning from cardiopulmonary bypass, refractory ventricular failure and mechanical complications due to acute myocardial infarction. TPCH survival was poorer than Benchmark in the settings of preoperative support in the high risk patient undergoing coronary artery bypass surgery and ischaemia related to intractable ventricular arrhythmias. IABP complication rates were higher in the TPCH series than Benchmark owing to an increased rate of access site bleeding. The pre-emptive use of IABP is gaining popularity 16 . Beginning with preoperative support of high risk patients undergoing coronary artery bypass graft surgery, practice has developed to incorporate support during percutaneous coronary intervention as a principal IABP indication. The growing acceptance surrounding pre-emptive IABP and earlier intervention in the course of patient illness has seen a dramatic increase in the overall use of the IABP. Use of the IABP at TPCH has increased by Despite TPCH increasing pre-emptive IABP use in the settings of catheter laboratory support and preoperative support over the 11 years, weaning from cardiopulmonary bypass remains the principal indication. A comparison of IABP indications between TPCH and Benchmark found most to demonstrate statistical lay only in two areas. In contrast to Benchmark, TPCH application of IABP was greater when weaning from cardiopulmonary bypass and fewer when supporting catheter laboratory procedures. Many reasons have been proposed for variations in IABP practice including controversy concerning the indications for use and differing philosophies [19] [20] [21] . Additionally IABP is still regarded and registered as a complication rather than a therapy 21 . It is likely the variation between TPCH and Benchmark indications represents a lack of consensus on the indications for IABP use.
like The Benchmark Counterpulsation Outcomes rates as well as an increased use (Figure 1 ). Improvement in TPCH mortality was demonstrated severity of illness measure not originally calibrated for cardiac surgical patients, its predictive power has shown to be discriminatory [22] [23] [24] . In this series the with in-hospital mortality despite a predominance of cardiothoracic patients (Figure 3 ). Considering this, uniform application of a general measure of patient score, may be appropriate in the cardiothoracic setting.
between TPCH and Benchmark over this 11-year series demonstrates an equivalence of in-hospital mortality associated with weaning from cardiopulmonary bypass and a higher mortality in the setting of preoperative support. It is interesting to note TPCH over the past 11 years indicate greater application of pre-emptive IABP, it is apparent TPCH practitioners are more likely to undertake IABP intraoperatively than preoperatively, suggesting the superior outcome for intra/postoperative patients in the TPCH series cannot readily be dismissed on the basis of excluding could be argued those TPCH patients receiving intra/postoperative IABP were of a lower acuity as they were stable enough preoperatively to not require IABP, patient characteristics in both TPCH and Benchmark series were similar indicating this was not the case (Table 1) 
Study limitations
Comparison between TPCH and The Benchmark Counterpulsation Outcomes Registry could be seen of Benchmark Counterpulsation Outcomes Registry involvement, results may not be representative of the entire spectrum of clinical practice. Additionally, as could be expected with any large scale multinational registry, any site to site variation in personnel or resources allocated to the registry may impact upon the accuracy of some records. It must also be considered all data is observational and some TPCH data has been collected retrospectively. Furthermore, owing to the retrospective nature of this study, it is recognised comparison of IABP usage and overall management of that particular indication, but rather distribution of overall IABP use in relation to the indication.
Concluding remarks
The greatest use of pre-emptive IABP occurs 16 . This impacts heavily upon the results of The Benchmark Counterpulsation Outemptive IABP has been adopted at TPCH, insertion following cardiopulmonary bypass remains high, while supportive use within the catheter laboratory is comparatively low. Despite the variance in IABP indication between TPCH and The Benchmark
